| Literature DB >> 30613797 |
Yeya Ds Sarro1, Bourahima Kone1, Bassirou Diarra1, Alisha Kumar2, Ousmane Kodio1, Djeneba B Fofana1, Chad J Achenbach2, Abdoul H Beavogui3, Moussa Seydi4, Jane L Holl2, Babafemi Taiwo2, Souleymane Diallo1, Seydou Doumbia1, Robert L Murphy2, Sally M McFall2, Mamoudou Maiga1,2.
Abstract
Tuberculosis (TB) is the deadliest infectious disease in the world which disproportionately affects low-and-middle-income countries (LMICs) where diagnostic resources and treatment options are limited. The incidence of pulmonary non-tuberculous mycobacteria (NTM) disease is also rapidly increasing in these regions traditionally dominated by TB infections. This poses significant diagnostic and treatment challenges, since these two diseases are often indistinguishable clinically or by sputum smear microscopy (SSM), the most commonly used TB diagnostic tool in LMICs. Consequently, NTM-infected patients usually receive unnecessary TB treatment for months. TB patients with NTM co-infections may also be treated incorrectly due to inaccurate SSM and Xpert™ MTB/RIF (M. tuberculosis./rifampin) results. These issues complicate the management of patients and contribute to the worsening of the current TB and NTM epidemiological features including development of drug resistant strains. It is therefore critical to develop improved diagnostic tools to accurately distinguish these two different pathogens that have many similar clinical and epidemiological features but have different treatment regimens. In this review, we will discuss limitations with current diagnostic tools and the need to develop novel techniques that can accurately and simultaneously diagnose TB and NTM disease._.Entities:
Keywords: diagnostic; epidemiology; non-tuberculous mycobacteria; tuberculosis
Year: 2018 PMID: 30613797 PMCID: PMC6319944 DOI: 10.15761/CMID.1000144
Source DB: PubMed Journal: Clin Microbiol Infect Dis ISSN: 2398-8096